Updated research demonstrates sustained viability of stem cell treatment for patients suffering from Crohn’s disease.
Takeda and TiGenix have presented 52-week data on their allogeneic expanded adipose-derived stem cells in Crohn’s disease patients with treatment-refractory complex perianal fistulas. The data show the Cx601 stem cells continue to outperform placebo one year after administration.
An overview of the 52-week data was shared at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO). The abstract includes treatment-related adverse event data that were absent from TiGenix’s original release, but included in subsequent presentations.
The data confirms the positive safety profile seen in the initial 24-week results. The rate of treatment-emergent adverse events was lower in the Cx601 cohort than the placebo plus standard of care arm at both time points. The same is true when only serious adverse events are analyzed.
